AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$LQDA

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.

Original reporting
finance.yahoo.com
Published Nov 10, 2026, 6:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 6:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Liquidia Q3 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$LQDANeutralMed
01

Why it matters

The earnings beat and cash strength are offset by a sizable settlement liability, leaving investors uncertain about near‑term guidance.

02

Market read

First‑time Q3 earnings disclosure for a small‑cap biotech; provides fresh data for positioning ahead of Q4 guidance.

03

What to watch

Upcoming data from RE‑SPIRE and AMPLIFY‑PAH trials could materially improve future revenue outlook.

Relevance 7/10Novelty 8/10Timing: post‑market Q3 release, with guidance expected early January

Background

Liquidia Corp. (NASDAQ:LQDA) reported Q3 results, detailing a $389.7M settlement, cash position, and pipeline updates.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Q3 earnings disclosed $140.5M adjusted EBITDA, $389.7M settlement charge and cash balance, plus no guidance and upcoming Q4 results.

Expected impact

potential pressure as investors weigh the settlement cost against strong cash and earnings growth

Evidence & confidence

The settlement is a material cash outflow through 2027, while the company reports solid operating metrics and no near‑term guidance, likely leading to a cautious market reaction.

Market effects

Sector

Highlights cash‑intensive settlement risk for biotech firms developing inhaled therapies.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche pulmonary‑hypertension market.

Counterpoint

What could challenge this read

The settlement charge may be over‑estimated by the market; strong cash and EBITDA could support upside.

Key entities

  • company
    Liquidia Corporation

    Biopharmaceutical company focused on pulmonary hypertension therapies.

Read at source← All news

StoryLiquidia reports Q3 2026 loss of $236.3 M after $389.7 M litigation settlement, revenue beats estimates

Also covered by

2 outlets

Related articles

$LQDAMed

BTIG raises Liquidia stock price target to $87 on strong demand

BTIG raised its price target for Liquidia Technologies (LQDA) to $87 from $70, citing strong demand for Yutrepia and increased 2027 EPS estimates. LQDA's Q3 revenue beat expectations at $225.3M, with Yutrepia sales up 31%, though GAAP EPS loss was $2.64 due to a $389.7M settlement charge. Jefferies also raised its target to $62, maintaining a Buy rating.

investing.com
$LQDAMed

Jefferies raises Liquidia stock price target to $62 on revenue growth

Jefferies raised its price target on Liquidia (NASDAQ:LQDA) to $62 from $55, maintaining a Buy rating. The company reported Q3 revenue of $222.7M, up 31% sequentially, with a GAAP EPS loss of $2.64 due to a $389.7M settlement charge. Adjusted EBITDA rose to $140.5M, and the stock has returned 76% over the past year. Jefferies expects 2027 revenue to reach $910M, citing strong growth in pulmonary arterial hypertension treatments.

investing.com
$LQDAMedAI 8/10

Why is Liquidia stock gaining today?

Liquidia Corporation (LQDA) shares rose 1.4% in pre-market trading after reporting Q3 2026 results. Revenue of $225.3M beat estimates, driven by $222.7M in YUTREPIA sales, up 31% from the prior quarter. A $389.7M litigation charge resulted in a GAAP net loss of $2.64 per share, but operational metrics showed growth, including record patient shipments and an expanding prescriber base. The company's cash position increased to $396.1M.

investing.com
$LQDAMed

Liquidia Reports Strong Third-Quarter YUTREPIA Sales Growth

Liquidia (LQDA) reported Q3 2026 net sales of $222.7M for YUTREPIA, up 31% from Q2, with October patient shipments at a record high. The company settled litigation with United Therapeutics, incurring a $389.7M charge and a Q3 net loss of $236.3M. Non-GAAP adjusted EBITDA was $140.5M, up for the fifth consecutive quarter. Cash reserves were $396.1M at Q3's end. The FDA granted Fast Track designation to YUTREPIA for a new indication, and the company initiated two new studies.

tipranks.com